Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Here, we aimed to elucidate the differences in microbiota composition between patients with gout and those with asymptomatichyperuricemia (asHU) and determine the effect of uric acid-lowering therapy (ULT) on the gut microbiome. Materials and Methods: Stool samples from patients with asHU (n=8) and three groups of gout patients, i.e., acute gout patientsbefore ULT (0ULT, n=14), the same acute gout patients after 30-day ULT (30ULT, n=9), and chronic gout patients after ≥6-monthULT (cULT, n=18) were collected and analyzed using 16S rRNA gene-based pyrosequencing. The composition of microbial taxonomyand communities, species diversity, and relationships among microbial communities were elucidated by bioinformaticanalysis. Results: Gout patients showed less diverse gut microbiota than asHU patients. The microbiota of the asHU group exhibited a higherFirmicutes-to-Bacteroidetes (F/B) ratio and lower Prevotella-to-Bacteroides (P/B) ratio than the gout group; significantly, the F/Bratio increased in gout patients after ULT. Moreover, a balanced enterotype populated asHU patients compared to gout patients. Notably, the gut microbiota in asHU patients had a higher proportion of taxa with potentially anti-inflammatory effects comparedto the gut microbiota in gout patients. Conclusion: We found that microbial composition differs between asHU and gout patients. The differential gut microbiota inasHU patients may protect against gout development, whereas that in gout patients may have a role in gout provocation. ULT ingout patients altered the gut microbiota, and may help alleviate gout pathology and mitigate gout progression.
Abstract
Purpose: Here, we aimed to elucidate the differences in microbiota composition between patients with gout and those with asymptomatichyperuricemia (asHU) and determine the effect of uric acid-lowering therapy (ULT) on the gut microbiome. Materials and Methods: Stool samples from patients with asHU (n=8) and three groups of gout patients, i.e., acute gout patientsbefore ULT (0ULT, n=14), the same acute gout patients after 30-day ULT (30ULT, n=9), and chronic gout patients after ≥6-monthULT (cULT, n=18) were collected and analyzed using 16S rRNA gene-based pyrosequencing. The composition of microbial taxonomyand communities, species diversity, and relationships among microbial communities were elucidated by bioinformaticanalysis. Results: Gout patients showed less diverse gut microbiota than asHU patients. The microbiota of the asHU group exhibited a higherFirmicutes-to-Bacteroidetes (F/B) ratio and lower Prevotella-to-Bacteroides (P/B) ratio than the gout group; significantly, the F/Bratio increased in gout patients after ULT. Moreover, a balanced enterotype populated asHU patients compared to gout patients. Notably, the gut microbiota in asHU patients had a higher proportion of taxa with potentially anti-inflammatory effects comparedto the gut microbiota in gout patients. Conclusion: We found that microbial composition differs between asHU and gout patients. The differential gut microbiota inasHU patients may protect against gout development, whereas that in gout patients may have a role in gout provocation. ULT ingout patients altered the gut microbiota, and may help alleviate gout pathology and mitigate gout progression.
참고문헌 (40)
- Brucato A, "Management of hyperuricemia in asymptomatic patients : a critical appraisal", Eur J Intern Med, 74, pp.8~17 (2020)
- Dalbeth N, "Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout : a dual energy CT study", Ann Rheum Dis, 74, pp.908~911 (2015)
- Chhana A, "Factors influencing the crystallization of monosodium urate : a systematic literature review", BMC Musculoskelet Disord, 16, pp.296~ (2015)
- Joosten LA, "Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC", caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis, 2010, pp.62, 3237~3248
- Hosomi A, "Extra-renal elimination of uric acid via intestinal efflux transporter BCRP", ABCG2, 2012, pp.7, e30456~
- Takada T, "ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion", Nucleosides Nucleotides Nucleic Acids, 33, pp.275~281 (2014)
- Yun Y, "Intestinal tract is an important organ for lowering serum uric acid in rats", PLoS One, 12, pp.e0190194~ (2017)
- Jing Wang, "The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies", Critical Reviews in Food Science and Nutrition, 62(14), pp.3979~3989 (2021), Informa UK Limited[DOI]
- Guo Z, "Intestinal microbiota distinguish gout patients from healthy humans", Sci Rep, 6, pp.20602~ (2016)
- Shao T, "Combined signature of the fecal microbiome and metabolome in patients with gout", Front Microbiol, 8, pp.268~ (2017)
- Neogi T, "2015 gout classification criteria : an American College of Rheumatology", European League Against Rheumatism collaborative initiative, 2015, pp.67, 2557~2568
- Masella AP, "PANDAseq : paired-end assembler for illumina sequences", BMC Bioinformatics, 13, pp.31~ (2012)
- Edgar RC, "Search and clustering orders of magnitude faster than BLAST", Bioinformatics, 26, pp.2460~2461 (2010)
- Edgar RC, "UCHIME improves sensitivity and speed of chimera detection", Bioinformatics, 27, pp.2194~2200 (2011)
- Chong J, "Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data", Nat Protoc, 15, pp.799~821 (2020)
- Wemheuer F, "Tax4Fun2 : prediction of habitat-specific functional profiles and functional redundancy based on 16S rRNA gene sequences", Environ Microbiome, 15, pp.11~ (2020)
- Turnbaugh PJ, "An obesity-associated gut microbiome with increased capacity for energy harvest", Nature, 444, pp.1027~1031 (2006)
- Hjorth MF, "Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis", Int J Obes(Lond), 43, pp.149~157 (2019)
- Chu Y, "Metagenomic analysis revealed the potential role of gut microbiome in gout", NPJ Biofilms Microbiomes, 7, pp.66~ (2021)
- Kuo YW, "Lactobacillus reuteri TSR332 and Lactobacillus fermentum TSF331stabilize serum uric acid levels and prevent hyperuricemia in rats", PeerJ, 9, pp.e11209~ (2021)
- Wang H, "Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis", Nutrition, 62, pp.63~73 (2019)
- García-Arroyo FE, "Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage", PLoS One, 13, pp.e0202901~ (2018)
- Hsu CL, "Antiobesity and uric acid-lowering effect of Lactobacillus plantarum GKM3 in high-fat-diet-induced obese rats", J Am Coll Nutr, 38, pp.623~632 (2019)
- Yamazaki T, "Lactic acid bacterium, Lactobacillus paracasei KW3110, suppresses inflammatory stress-induced caspase-1 activation by promoting interleukin-10production in mouse and human immune cells", PLoS One, 15, pp.e0237754~ (2020)
- Suzuki H, "A specific strain of lactic acid bacteria, lactobacillus paracasei, inhibits inflammasome activation in vitro and prevents inflammation-related disorders", J Immunol, 205, pp.811~821 (2020)
- Cani PD, "Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia", Diabetologia, 50, pp.2374~2383 (2007)
- Di Pierro F, "Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries : results of a randomized, controlled study", Clin Cosmet Investig Dent, 7, pp.107~113 (2015)
- Kant R, "Genome sequence of the butyrate-producing anaerobic bacterium anaerostipes hadrus PEL 85", Genome Announc, 3, pp.e00224-15~ (2015)
- Carasi P, "Enterococcus durans EP1 a promising anti-inflammatory probiotic able to stimulate sIgA and to increase Faecalibacterium prausnitzii abundance", Front Immunol, 8, pp.88~ (2017)
- Liu X, "The altered gut microbiota of high-purine-induced hyperuricemia rats and its correlation with hyperuricemia", PeerJ, 8, pp.e8664~ (2020)
- Vieira AT, "Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice", J Leukoc Biol, 101, pp.275~284 (2017)
- Bernard NJ, "Rheumatoid arthritis : Prevotella copri associated with new-onset untreated RA", Nat Rev Rheumatol, 10, pp.2~ (2014)
- Pianta A, "Evidence of the immune relevance of Prevotella copri, a gut microbe, in patients with rheumatoid arthritis", Arthritis Rheumatol, 69, pp.964~975 (2017)
- Liu J, "Analysis of oral microbiota revealed high abundance of Prevotella intermedia in gout patients", Cell Physiol Biochem, 49, pp.1804~1812 (2018)
- Yuichi Maeda, "Host–microbiota interactions in rheumatoid arthritis", Experimental and Molecular Medicine, 51, pp.1~6 (2019), 생화학분자생물학회[DOI]
- Le Chatelier E, "Richness of human gut microbiome correlates with metabolic markers", Nature, 500, pp.541~546 (2013)
- Karlsson FH, "Gut metagenome in European women with normal, impaired and diabetic glucose control", Nature, 498, pp.99~103 (2013)
- Chalès G, "How should we manage asymptomatic hyperuricemia?", Joint Bone Spine, 86, pp.437~443 (2019)
- Senghor B, "Gut microbiota diversity according to dietary habits and geographical provenance", Hum Microbiome J, 7-8, pp.1~9 (2018)
- Méndez-Salazar EO, "Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism", Mol Med, 27, pp.50~ (2021)
